Gubra A/S Logo

Gubra A/S

Preclinical CRO and peptide drug developer for metabolic and fibrotic diseases.

GUBRA | CO

Overview

Corporate Details

ISIN(s):
DK0062266474
LEI:
254900T17RRFZONO6W53
Country:
Denmark
Address:
Hørsholm Kongevej 11 B, 2970 Hørsholm
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Gubra is a biotechnology company and preclinical Contract Research Organization (CRO) founded in 2008. The company operates a dual business model, providing specialized preclinical research services while simultaneously developing its own pipeline of peptide-based therapeutics. Gubra's core expertise lies in metabolic diseases (such as obesity, diabetes, and MASH) and fibrotic diseases. Its CRO services support pharmaceutical and biotech clients with advanced studies, including in vivo pharmacology and peptide chemistry. The drug discovery division focuses on advancing a proprietary portfolio of novel drug candidates, with research and development efforts also extending into inflammatory, CNS, respiratory, and women's health conditions. This integrated approach combines stable service revenue with the long-term potential of therapeutic innovation.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Gubra A/S and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Gubra A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Gubra A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lidds AB Logo
Develops a drug delivery platform for local, sustained-release oncology treatments.
Sweden LIDDS
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies to restore function in neurological & retinal diseases.
Israel LCTX
Lipidor AB Logo
Develops topical skin disease drugs using a lipid-based drug delivery platform.
Sweden LIPI
Lipigon Pharmaceuticals AB Logo
Develops RNA and small-molecule drugs for rare, lipid-related disorders.
Sweden LPGO
Lipum AB Logo
Develops novel antibody therapies for chronic inflammatory diseases like rheumatoid arthritis.
Sweden LIPUM
LYSOGENE Logo France LYS
Lytix Biopharma AS Logo
Develops oncolytic peptides that kill cancer cells and stimulate an anti-tumor immune response.
Norway LYTIX
Matricelf Ltd. Logo
Engineering autologous 3D tissue implants from patient cells to treat spinal cord injuries.
Israel MTLF
Mazaro N.V. Logo
Engineering patented, high-efficiency transmissions for vehicles and industrial drivelines.
Belgium MLMAZ
Medesis Pharma S.A. Logo
Biotech creating CNS and oncology therapies using a proprietary drug delivery platform.
France ALMDP

Talk to a Data Expert

Have a question? We'll get back to you promptly.